A small %Biotech company saw its shares trading higher during Tuesday’s session after the company announced its second quarter financial results for 2022. Some financial highlights from the press release were:
- Cash and cash equivalents were $20.1 million as of June 30, 2022
- Collaboration revenue was $38 thousand for the second quarter of 2022, as compared to $761 thousand for the corresponding quarter in 2021
- Both research and development expense and general and administrative expenses were down QoQ
This financial feat led share of %AyalaPharmaceuticals () to trade significantly higher during Tuesday’s session, reaching up to $1.48/share (+18.40%) at the session high. This move could be viewed as confirmation of the support found toward the end of July.
Ayala Pharmaceuticals Inc clinical-stage %Oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma-secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma-secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell-specific leukemia.
About AllPennyStocks.com Media Inc.:
AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders. Outside of the countless free content available to visitors, AllPennyStocks.com Pro (premium service) caters to traders looking for that trading edge by offering monthly stock picks, daily penny stock to watch trade ideas, market commentary and more.